R. Khodarahmi, B. Sayad, Masomeh Mehrabi, F. Najafi, R. Miladi, Zeinab Mohseni Afshar, F. Mansouri, M. Shirvani, M. Salimi, F. Shadmani
{"title":"sofosbuvir-velpatasvir附加治疗COVID-19患者的临床有效性和安全性:随机对照试验的研究方案和初步数据","authors":"R. Khodarahmi, B. Sayad, Masomeh Mehrabi, F. Najafi, R. Miladi, Zeinab Mohseni Afshar, F. Mansouri, M. Shirvani, M. Salimi, F. Shadmani","doi":"10.4103/jrptps.jrptps_46_21","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":16966,"journal":{"name":"Journal of Reports in Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical effectiveness and safety of sofosbuvir–velpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial\",\"authors\":\"R. Khodarahmi, B. Sayad, Masomeh Mehrabi, F. Najafi, R. Miladi, Zeinab Mohseni Afshar, F. Mansouri, M. Shirvani, M. Salimi, F. Shadmani\",\"doi\":\"10.4103/jrptps.jrptps_46_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":16966,\"journal\":{\"name\":\"Journal of Reports in Pharmaceutical Sciences\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Reports in Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jrptps.jrptps_46_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Reports in Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrptps.jrptps_46_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Clinical effectiveness and safety of sofosbuvir–velpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial
期刊介绍:
The Journal of Reports in Pharmaceutical Sciences(JRPS) is a biannually peer-reviewed multi-disciplinary pharmaceutical publication to serve as a means for scientific information exchange in the international pharmaceutical forum. It accepts novel findings that contribute to advancement of scientific knowledge in pharmaceutical fields that not published or under consideration for publication anywhere else for publication in JRPS as original research article. all aspects of pharmaceutical sciences consist of medicinal chemistry, molecular modeling, drug design, pharmaceutics, biopharmacy, pharmaceutical nanotechnology, pharmacognosy, natural products, pharmaceutical biotechnology, pharmacology, toxicology and clinical pharmacy.